Follow-up of Immune Response in Patients with Common Variable Immunodeficiency following SARS-CoV-2 Vaccination

In this study, we evaluated the humoral and cellular immune responses after four doses of mRNA-1273 and one BNT162b2 bivalent vaccine in a cohort of patients with CVID and XLA. The response in this population was lower than in the control group. However, the administration of the third dose improved the number of patients with seroconversion and the intensity of the humoral response, as well as the number of patients with a positive cellular response. Finally, the administration of the fourth and fifth doses improves the antibody titer and neutralization against wild type variant, but not against the prevalent XBB1.5 variant.PMID:38693777 | DOI:10.1093/cei/uxae039

Source: Clinical and Developmental Immunology - May 2, 2024 Category: Allergy & Immunology Authors: Juan Francisco Guti érrez-Bautista Irene D íaz-Alberola Mar ía Tarriño Mar ía Aguilera Fernando Cobo Juan Antonio Reguera Javier Rodr íguez-Granger Joaqu ín Mendoza Miguel Ángel López-Nevot Antonio Sampedro Source Type: research